RxDoctor Payments Data

Abdul Aadam, MD

Gastroenterology · Chicago, ILNPI 1013038744

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 69.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $35,098 and has fallen 83.3% since, to $5,869 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$137,839in general payments, 2019–2025

Across 347 payments — averaging $397.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$95K
  • US Endoscopy$15K
  • ERBE USA Inc$9K
  • Conmed Corporation$7K
  • Medtronic$6K
  • Cook Medical LLC$2K
  • plus $3K from 4 others

What the payments were for

  • Consulting fees$38,87528%
  • Speaking & faculty fees$80,46358%
  • Travel & lodging$8,7556%
  • Food & beverage$9,5987%
  • Entertainment$1480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,839 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$166,615
Medicare patients
368
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase11$25,384
VoqueznaVonoprazan Fumarate13$8,527
TrulancePlecanatide11$5,725
Sucralfate33$3,550
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg147$2,643
Omeprazole152$2,047
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,601
Acetaminophen-CodeineAcetaminophen With Codeine26$1,558
Pantoprazole Sodium31$418
Nystatin22$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,250$5,72511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →